NuCana plc, a clinical-stage biopharmaceutical firm focused on developing cancer therapies, is utilizing its proprietary ProTide technology to conceptualize new treatments. The company's primary drug, NUC-3373, is a chemical entity made from the nucleoside analog 5-fluorouracil that is undergoing Phase 1b/2 trials for the treatment of advanced colorectal cancer. NUC-3373 is also undergoing Phase 2 trials for the second-line treatment of patients with advanced colorectal cancer and is being tested in Phase 1b/2 modular trials in combination with the PD-1 inhibitor pembrolizumab for the treatment of patients with advanced solid tumors and in conjunction with docetaxel for those with lung cancer. Additionally, the company is developing NUC-7738, a ProTide transformation of 3'-deoxyadenosine that is in Phase 1/2 clinical trial for the treatment of patients with advanced solid tumors and hematological malignancies. NuCana has a solo research, collaboration, and license agreement with Cardiff University and University College Cardiff Consultants Ltd. for the design, synthesis, characterization, and evaluation of ProTides, as well as an assignment, license, and collaboration agreement with Cardiff ProTides Ltd. Having changed its name to NuCana plc from NuCana BioMed Limited in August 2017, the company has been in operation since 1997 and is headquartered in Edinburgh, United Kingdom.
NuCana plc's ticker is NCNA
The company's shares trade on the NASDAQ stock exchange
They are based in Edinburgh, Scotland
There are 11-50 employees working at NuCana plc
It is http://www.nucana.com/index.html
NuCana plc is in the Healthcare sector
NuCana plc is in the Biotechnology industry
The following five companies are NuCana plc's industry peers: